Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval
A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical giant a way to retain some market share as the original intravenously infused formulation — its top-selling product — faces patent expirations. The approval announced Friday covers…